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SUMMARY OF ISSUES AND RECOMMENDATIONS  
Issue 1: Which methodology should be used: Factor V Leiden DNA testing or functional activated protein C 
(APC) resistance testing?  
Recommendation 1  
When appropriate clinical care requires testing for the factor V Leiden allele, either direct DNA-based 
genotyping or a factor V Leiden-specific functional assay is recommended. Patients who test positive by a 
functional assay should then be further studied with the DNA test for confirmation and to distinguish 
heterozygotes from homozygotes. Patients on heparin therapy or with known lupus anticoagulant should 
proceed directly to molecular testing if the modified functional assay is not used. When relatives of individuals 
known to have factor V Leiden are tested, the DNA method is recommended.  
Issue 2: Who should be tested?  
Recommendation 2  
Opinions and practices regarding factor V Leiden testing vary. Some physicians advocate testing of all patients 
with venous thrombosis except when active malignancy is present. Others exclude testing in patients over age 
60 in the absence of a family history of thrombosis or a previous thrombotic event.  
There is growing consensus that testing should be performed in at least the following circumstances (these are 
the same general recommendations for testing for any thrombophilia):  
z Age <50, any venous thrombosis.  
z Venous thrombosis in unusual sites (such as hepatic, mesenteric, and cerebral veins).  
z Recurrent venous thrombosis.  
z Venous thrombosis and a strong family history of thrombotic disease.  
z Venous thrombosis in pregnant women or women taking oral contraceptives.  
z Relatives of individuals with venous thrombosis under age 50.  
z Myocardial infarction in female smokers under age 50.  
Testing may also be considered in the following situations:  
z Venous thrombosis, age >50, except when active malignancy is present.  
z Relatives of individuals known to have factor V Leiden. Knowledge that they have factor V Leiden may 
influence management of pregnancy and may be a factor in decision-making regarding oral 
contraceptive use.  
z Women with recurrent pregnancy loss or unexplained severe preeclampsia, placental abruption, 
intrauterine fetal growth retardation, or stillbirth. Knowledge of factor V Leiden carrier status may 
influence management of future pregnancies.  
Random screening of the general population for factor V Leiden is not recommended.  
Routine testing is not recommended for patients with a personal or family history of arterial thrombotic disorders 
(e.g., acute coronary syndromes or stroke) except for the special situation of myocardial infarction in young 
female smokers. Testing may be worthwhile for young patients (<50 years of age) who develop acute arterial 
thrombosis in the absence of other risk factors for atherosclerotic arterial occlusive disease. 
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Issue 3: Should testing be offered to individuals with environmental risk factors?  
Recommendation 3  
Factor V Leiden testing is recommended in women with venous thromboembolism during pregnancy or oral 
contraceptive use. In contrast to general screening before administration of oral contraceptives, targeted testing 
of women with a personal or family history of venous thrombosis is advisable. Routine screening for factor V 
Leiden in asymptomatic womencontemplating or using oral contraceptives is not recommended, except for 
those with a personal history of thromboembolism or other medical risk factors. Those women with a family 
history of thromboembolism, APC resistance, or documented factor V Leiden mutation should be counseled 
about their risks and options and considered for testing depending on the overall clinical situation. Women with 
a history of recurrent late-trimester fetal loss should also be considered for testing. Whether or not the woman 
smokes would not alter these recommendations. Screening of asymptomatic individuals with other recognized 
environmental risk factors such as surgery, trauma, paralysis, and malignancy is not necessary or 
recommended, since all such individuals should receive appropriate medical prophylaxis for thrombosis 
regardless of carrier status.  
Issue 4: Should patients found to be positive for factor V Leiden or APC resistance be tested for any of the other 
heritable thrombophilic risk factors?  
Recommendation 4  
Patients testing positive for factor V Leiden or APC resistance should be considered for molecular genetic 
testing for the most common other thrombophilias with overlapping phenotype for which testing is easy and 
readily available. At present, only the prothrombin 20210A variant fits these criteria. It is present in 1-2% of the 
general population, its involvement in venous thromboembolism is well-established, and the DNA test is as 
simple as that for factor V Leiden (with which it can even be multiplexed). Protein S, protein C, and antithrombin 
III deficiencies are too genetically heterogeneous for routine molecular genetic testing, but testing by functional 
coagulation assays may be considered, especially if there is a strong family history of venous thrombosis. 
Hyperhomocysteinemia should be considered and tested (in most cases by measuring plasma homocysteine 
levels) as another potential risk factor in those found to be positive for factor V Leiden. Patients with classic 
homocystinuria are at extremely elevated risk of thromboembolism and should probably be tested for other 
available thrombophilic risk factors.  
Issue 5: Should testing for other heritable thrombophilic factors be performed simultaneously with factor V 
Leiden testing?  
Recommendation 5  
Physicians ordering factor V Leiden on a venous thrombosis patient for any of the indications recommended 
here should also consider the utility of functional, biochemical, and molecular screening for other heritable 
thrombophilic factors, especially prothrombin 20210A and plasma homocysteine levels.  
Issue 6: Are there any other factor V mutations in addition to factor V Leiden which should be tested?  
Recommendation 6  
The factor V Leiden (R506Q) mutation is currently the only molecular analysis of the factor V gene indicated in 
the routine workup of thrombotic risk.  
Issue 7: What are the recommended methodologies and quality assurance standards for performing these 
tests?  
Recommendation 7  
The factor V Leiden mutation test should be performed using any of the accepted technical approaches as long 
as they have been properly validated by the laboratory, while adhering to current ACMG/CAP quality assurance 
guidelines for molecular genetic testing.  
Issue 8: What are the appropriate pre- and postanalytic procedures to be followed in factor V Leiden testing?  
Recommendation 8  
Formal informed consent should not be required for factor V Leiden testing, but individuals being tested should 
be made aware that this is a genetic test, that test results have implications about risk in other family members, 
and that there may be attendant issues of confidentiality and possible insurance discrimination. The laboratory's 
report should state explicitly the relative risk implications for factor V Leiden heterozygotes and homozygotes, 
the risk that other relatives may have the mutation, and the recommendation, if indicated, for testing for other 
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It is important for individuals testing positive for factor V Leiden to understand the risk implications and genetic 
implications of their result. Patients should be counseled about these implications by their physician or genetic 
counselor.  
BACKGROUND  
Normal hemostasis requires a delicate balance between the natural procoagulant and anticoagulant systems. 
Both of these systems are subject to disruption by either inherited or acquired (including both intrinsic and 
environmental) defects. Inherited defects associated with clinical bleeding disorders (e.g., hemophilia A and B 
and von Willebrand disease) have been known and studied for centuries. In contrast, inherited defects causing 
thrombosis have been recognized more recently. These heritable thrombophilias (hypercoagulabilities) include 
factor V Leiden (R506Q mutation), the prothrombin 20210A mutation, antithrombin III deficiency, and 
deficiencies of protein C and protein S.  
The incidence of venous thrombosis is about 1 per 1,000 person-years1 and leads to 50,000 deaths annually in 
this country.2 It is a multifactorial disorder, involving one or a combination of genetic risk factors and acquired or 
environmental conditions such as pregnancy, oral contraceptive use, estrogen therapy, malignancy, stroke with 
extremity paresis, trauma, surgery, or immobility.3 The risk increases with the number of genetic and/or 
environmental conditions present, though venous thromboembolism can occur in the absence of known risk 
factors. Known genetic causes are present in approximately 25% of unselected venous thrombosis cases and 
up to 63% of familial cases.4  
Factor V R506Q (Leiden), causing activated protein C (APC) resistance, was discovered in 1994 and is the 
most common genetic risk factor for venous thrombosis. It is present in 5% of Caucasian Americans, 20% of 
idiopathic first venous thrombosis cases, and 60% of venous thrombosis cases in pregnant women. Knowledge 
of the presence of factor V Leiden in patients and relatives can influence management and prevention of venous 
thrombosis in some cases. Factor V Leiden has also been associated with increased risk of recurrent pregnancy 
loss and placental infarction.  
The procoagulant system  
The normal function of the procoagulant system is to target a hemostatic plug containing platelets and fibrin into 
a breach within the inside lining of "injured" blood vessels. The procoagulant system has been characterized as 
a "cascade" of amplifying enzymatic reactions leading to the final serine protease, thrombin. The procoagulant 
system is triggered by exposure of the coagulation activator, tissue factor, to circulating blood. Tissue factor 
normally is sequestered from the circulation within the wall of blood vessels and only exposed to blood after 
vessel wall injury. Exposed (or expressed) tissue factor binds circulating factor VIIa, and in the presence of 
anionic phospholipid and divalent cations (e.g., calcium), forms a factor X-ase complex. This factor X-ase 
complex either directly cleaves ("activates") factor X to Xa, or activates factor IX to IXa, by limited proteolysis. 
Factor IXa binds factor VIIIa to form a second factor X-ase complex, which activates factor X to Xa. Factor Xa 
binds factor Va to form the prothrombinase complex, which activates prothrombin to thrombin. Thrombin 
produces a hemostatic plug by cleaving fibrinogen to form fibrin monomers, by activation of platelets, and by 
activating factor XIII to XIIIa which crosslinks strands of fibrin monomers to form a stable hemostatic plug. In a 
feedback amplification loop, thrombin also increases its own production by activating factors V, VIII, and XI. 
Together factors Va and VIIIa can potentially increase the rate of thrombin generation by one million-fold and 
provide major control points for the regulation of thrombin generation.  
The anticoagulant system  
The function of the natural anticoagulant system is to confine a normal hemostatic plug to the site of vessel wall 
injury and to prevent the beneficial thrombus from propagating to form a pathologic thrombus, which occludes 
the lumen of the vessel or embolizes to occlude distant vessels. The recognized anticoagulant components of 
this system include antithrombin III, protein C, and protein S. The anticoagulant system is activated in parallel 
with the procoagulant system. Protein C is a circulating vitamin K-dependent zymogen, which is activated to 
APC, the active enzyme, by the thrombin-thrombomodulin complex. APC functions as a natural anticoagulant by 
inactivating (via proteolysis) procoagulant factors Va and VIIIa in the presence of protein S. Antithrombin III is a 
serine protease inhibitor (SERPIN) and acts as a pseudosubstrate to irreversibly inhibit thrombin by covalently 
binding the thrombin enzymatic active site. The rate of thrombin inhibition by antithrombin III is increased 
markedly by glycosaminoglycans (e.g., heparin). Familial reductions in plasma antithrombin III, protein C, or 
protein S activity due to either reduced plasma protein levels (i.e., altered protein expression), or normal levels 
of a dysfunctional protein (i.e., altered protein structure), are strongly associated with deep vein thrombosis and 
pulmonary embolism (venous thromboembolism), and validate the important role of these proteins in the natural 
anticoagulant system. Altogether, however, the prevalence of these previously recognized familial 
thrombophilias among venous thromboembolism patients ranges from 5 to 20%, depending on cohort 
selection.5  
Activated protein C resistance and the factor V Leiden mutation  
The report of three unrelated probands and their families with idiopathic recurrent venous thromboembolism 
whose plasma was resistant to the anticoagulant effect of exogenously added APC6 has provided exciting new 
insights into the etiology of venous thromboembolism. Early epidemiologic data suggested that an abnormally 
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autosomal dominant or semidominant inheritance pattern.7 Factor Va isolated from APC-R patient plasma was 
resistant to inactivation by APC.8 Subsequent work identified a single point mutation (G to A) at nucleotide 1691 
of the factor V gene, which results in substitution of a glutamine for arginine at residue 506 (R506Q), one of 
three APC cleavage sites (R306, R506, R679).9-13 This mutation is known as factor V Leiden. Initial APC 
cleavage at the R506 position is required for optimal exposure and subsequent rapid inactivation of factor V by 
APC cleavage at positions R306 and R679.14,15 Depending on the APC resistance functional assay used and 
the cut-off values for defining an abnormal result, the factor V Leiden mutation may account for 85-95% of 
patients with APC resistance. Recent studies show that APC-R with normal factor V R506 genotype is a risk 
factor for venous thrombosis.16,17  
APC resistance is the most common recognized abnormality of coagulation among patients with venous 
thromboembolism. The factor V Leiden mutation is carried in heterozygous form by about 5% of the Caucasian 
population; it is rarer in Hispanic-Americans, rarer still in African-Americans, and virtually absent in Africans and 
Asians.18,19 It is believed to produce a relative risk of venous thrombosis of about 7-fold in the heterozygous 
state and about 80-fold in the homozygous state. It is the most common hereditary thrombophilia and is found in 
roughly 11-20% of individuals of all ages presenting with their first episode of venous thrombosis.20,21 When 
venous thrombosis patients are selected to be under 50 years old and/or to have recurrent thrombosis, up to 
40% have the factor V Leiden genotype. Because only a single mutation is involved, testing by any number of 
simple and inexpensive molecular genetic methods is possible.  
CHARGE TO THE WORKING GROUP  
Given the high allele frequency of the factor V Leiden mutation and some of the other inherited thrombophilia 
defects, questions regarding criteria for testing and the possibility of population screening have been raised. The 
issues are quite complex and were referred to a specially appointed working group of the ACMG for 
deliberation. It should be noted at the outset that the group's proposed recommendations as presented here 
were based on the best scientific evidence available at the time. However, the heritable thrombophilia field is 
changing rapidly as more clinical studies to further define the genetic risks are completed and additional 
interacting factors are identified, making the attempt to develop recommendations something of a moving target. 
As such, these recommendations should be understood as being subject to change as new knowledge accrues.  
ISSUES AND RECOMMENDATIONS  
1. Which methodology should be used: Factor V Leiden DNA testing or functional APC resistance testing?  
APC resistance due to factor V Leiden can be diagnosed by functional analysis of the intrinsic or extrinsic 
coagulation pathway or by direct molecular genetic testing for the R506Q mutation in the factor V gene. The 
coagulation assay for APC resistance is based on a functional analysis of the anticoagulant effect on patient 
plasma of exogenously added APC. As an anticoagulant, APC normally decreases the rate of thrombin 
generation in plasma. Available APC resistance assays test for the APC anticoagulant effect via either 
prolongation of clotting time (e.g., activated partial thromboplastin time [aPTT], prothrombin time [PT], etc.), or 
by direct measurement of thrombin generation using a chromogenic substrate. The traditional functional test, 
based on the partial thromboplastin time (aPTT), casts a wider net, since not all cases of clinical APC resistance 
are due to the factor V Leiden mutation. However, it lacks specificity for factor V Leiden and is subject to 
perturbation by acute phase reactants, pregnancy, oral contraceptives, the acquired lupus anticoagulant 
syndrome (antiphospholipid antibody), and yet undefined factors.22 In addition, it cannot be used in patients 
receiving heparin or warfarin sodium anticoagulant therapy, and it is much less efficient at distinguishing factor 
V Leiden heterozygotes from homozygotes due to extensive overlap in the assay values. Making this distinction 
is clinically important since homozygotes have about a 10-fold higher risk of thrombotic events than 
heterozygotes. A recent modification of the functional assay, involving dilution of patient plasma into factor V-
deficient plasma, provides quite reliable differentiation of heterozygotes and homozygotes and little or no 
interference by the other clinical factors, but narrows the specificity to that of the mutation assay, so that cases 
of APC resistance due to other causes will be missed.8,23,24 Despite this drawback, the modified assay has 
been adopted widely; therefore, any consideration of the relative merits of molecular versus coagulation testing 
must take this into account.  
Other points of comparison between the tests are cost and convenience of specimen handling. Currently, the 
cost for the DNA test is higher than that for the functional test (though this is likely to change with the advent of 
new automated DNA technologies). The DNA test requires blood at room temperature, while the APC 
resistance test requires citrated frozen plasma, which must be prepared using centrifugation.  
Recommendation 1  
When appropriate clinical care requires testing for the factor V Leiden allele, either direct DNA-based 
genotyping or a factor V Leiden-specific functional assay is recommended. Patients who test positive by a 
functional assay should then be further studied with the DNA test for confirmation and to distinguish 
heterozygotes from homozygotes. Patients on heparin therapy or with known lupus anticoagulant should 
proceed directly to molecular testing if the modified functional assay is not used. When relatives of individuals 
known to have factor V Leiden are tested, the DNA method is recommended.  
2. Who should be tested?  
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usefulness of identifying the mutation and the clinical criteria for testing. Testing would clearly be helpful if it 
identified individuals with increased recurrence risk who could then be considered for long-term antithrombotic 
therapy. In general, for patients with a first, objectively documented venous thromboembolism, the risk of 
recurrence is highest during the first 6-12 months after the event, with a cumulative recurrence rate of about 
30% by 8-10 years.25,26 Patients with persistent risk factors for venous thromboembolism (e.g., cancer, stroke 
with extremity paresis, obesity) and patients with idiopathic venous thromboembolism are at highest risk for 
recurrence.27,28 It is not yet clear whether factor V Leiden heterozygosity increases risk of recurrent venous 
thrombosis. A few studies21,29 found increases in recurrence risk of 4- to 5-fold and 2-fold, respectively, but 
other studies found no increase.30,31 Currently, identification of factor V Leiden heterozygosity does not 
change the therapeutic approach to venous thrombosis or subsequent prophylaxis in most patients. For patients 
with recurrent venous thromboembolism, some clinicians recommend lifelong anticoagulation therapy, 
regardless of whether a genetic risk factor is present,32 while other clinicians would test patients to assist in 
decision-making about indefinite anticoagulant therapy and genetic counseling of patients and their families.  
Despite the reservations listed above, there are several arguments in favor of testing for factor V Leiden. In 
some circumstances, knowledge of the factor V Leiden status strongly influences patient management. Testing 
will identify factor V Leiden homozygosity in 1.5% of patients under age 70 with a first episode of venous 
thromboembolism in the absence of malignancy.33 Lifetime antithrombotic prophylaxis should be considered for 
homozygotes after a thrombotic event.34,35 This approach is also the case for venous thrombosis patients 
heterozygous for both factor V Leiden and the prothrombin 20210A mutation, which is not an uncommon 
finding, in whom recurrence risk has been shown to be high.36 However, the decision must take into account 
the coexistence of bleeding tendencies and other contraindications. The risk of major bleeding with chronic 
warfarin therapy may reach 8% per year,37 and there are no studies which provide good estimates of the 
absolute risk of venous thromboembolism among homozygous carriers. Thus, we do not know what the true 
risk-benefit ratio is of life-long warfarin anticoagulation for these patients.  
A benefit of identifying the factor V Leiden mutation in patients with venous thrombosis is that asymptomatic 
family members can opt to determine whether they are at increased risk for venous thrombosis due to this risk 
factor. The lifetime risk for venous thrombosis in factor V Leiden heterozygotes is approximately 10%38 and for 
homozygotes is >80%.33 Knowledge of factor V Leiden status in asymptomatic relatives can be useful in 
guiding antithrombotic prophylaxis during periods of risk, particularly postpartum,39 and might allow for 
heightened awareness of presenting signs of deep vein thrombosis. Female relatives may also wish to know 
their status before deciding to use oral contraceptives.  
Factor V Leiden increases the risk for recurrent fetal loss, possibly due to placental thrombosis.40,41 Testing in 
women with recurrent pregnancy loss may be important, since antithrombotic therapy may be effective in 
allowing these women to carry a pregnancy to term.42 Factor V Leiden has also been associated with increased 
risk of severe preeclampsia, placental abruption, unexplained intrauterine fetal growth retardation, and 
stillbirth.41,43,44 On the other hand, given that factor V Leiden-associated thrombophilia is an adult-onset 
disorder of low penetrance, fetal testing is not indicated. For similar reasons, routine newborn screening for 
factor V Leiden is not recommended.  
Increasing age is a strong independent risk factor for venous thrombosis, and for this reason, many physicians 
do not attempt to identify genetic risk factors in elderly patients with venous thrombosis. However, at least two 
studies have shown that among factor V Leiden carriers, the first lifetime episode of VTE usually occurs after 
age 50 years, suggesting that testing for this mutation should not be limited to young patients.38,45 In another 
study, 26% of men over age 60 with a first episode of idiopathic venous thromboembolism had factor V 
Leiden.21  
The weight of currently available evidence suggests that arterial thrombosis, myocardial infarction, and stroke 
are not associated with factor V Leiden.21 An exception is myocardial infarction in young (<45 years old) female 
smokers, in whom the combination of the two factors increases the relative risk 32-fold.46 Factor V Leiden has 
also been implicated in younger adults (<50) who develop arterial thrombosis in the absence of other risk 
factors for atherosclerotic disease.47,48  
Recommendation 2  
Opinions and practices regarding factor V Leiden testing vary. Some physicians advocate testing of all patients 
with venous thrombosis except when active malignancy is present. Others exclude testing in patients over age 
60 in the absence of a family history of thrombosis or a previous thrombotic event.  
There is growing consensus that testing should be performed in at least the following circumstances (these are 
the same general recommendations for testing for any thrombophilia):  
 Age <50, any venous thrombosis.  
 Venous thrombosis in unusual sites (such as hepatic, mesenteric, and cerebral veins).  
 Recurrent venous thrombosis.  
 Venous thrombosis and a strong family history of thrombotic disease.  
 Venous thrombosis in pregnant women or women taking oral contraceptives.  
 Relatives of individuals with venous thrombosis under age 50.  
 Myocardial infarction in female smokers under age 50.  
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 Venous thrombosis, age >50, except when active malignancy is present.  
 Relatives of individuals known to have factor V Leiden. Knowledge that they have factor V Leiden may 
influence management of pregnancy, and may be a factor in decision-making regarding oral 
contraceptive use.  
 Women with recurrent pregnancy loss or unexplained severe preeclampsia, placental abruption, 
intrauterine fetal growth retardation, or stillbirth. Knowledge of factor V Leiden carrier status may 
influence management of future pregnancies.  
Random screening of the general population for factor V Leiden is not recommended.  
Routine testing is not recommended for patients with a personal or family history of arterial thrombotic disorders 
(e.g., acute coronary syndromes or stroke) except for the special situation of myocardial infarction in young 
female smokers. Testing may be worthwhile for young patients (<50 years of age) who develop acute arterial 
thrombosis in the absence of other risk factors for atherosclerotic arterial occlusive disease. Neither prenatal 
testing nor routine newborn screening is recommended.  
3. Should testing be offered to individuals with environmental risk factors?  
Some individuals are at increased risk of venous thromboembolism due to environmental exposures, and some 
of these risks are synergistic with factor V Leiden if both are present, with combined relative risk values many 
times higher than those for either condition alone. Examples include oral contraceptive use, pregnancy, and 
estrogen therapy. Patients facing commonly recognized environmental risks such as surgery, trauma, paralysis, 
and malignancy should be receiving appropriate venous thromboembolism prophylaxis regardless of genetic 
status. However, involvement of an environmental trigger for venous thrombosis does not preclude the possible 
presence of factor V Leiden or other genetic risk factor.  
The environmental factor most extensively discussed in this context is oral contraceptive use in women, which 
produces a 30-fold increase in thrombotic risk when the factor V Leiden mutation is also present. Some have, 
therefore, proposed that women contemplating oral contraceptive therapy be screened for factor V Leiden and 
that counseling be provided and an alternative method of birth control be offered to those who test positive. On 
the other hand, convincing arguments can be made that widespread screening on such a large population 
would not be cost-effective based on number of lives actually saved and the increased risk of pregnancy and 
other complications in those women obligated to turn to other methods of contraception. Despite the popular 
concept, it remains controversial whether or not smoking while on oral contraceptives increases the relative risk; 
recent evidence suggests a synergistic effect on risk of myocardial infarction and cerebral thromboembolic 
stroke, but not on venous thromboembolism, which is the primary phenotype of factor V Leiden.49,50  
Converting these hypothetical risks into probabilistic numbers is illustrative of the complexities involved in this 
sort of decision-making. The increased risk of thrombosis caused by oral contraceptive use alone is about 4-
fold; in the setting of factor V Leiden heterozygosity, this risk increases to 30-fold.51,52 While these relative 
risks may seem high, the absolute risk of thrombotic events in this patient population (primarily young women) is 
quite low.53 The baseline incidence of venous thromboembolism in women under age 44 is about 5 events per 
100,000 woman-years. Given a mortality rate from venous thromboembolism in this age group of 1%, and the 
increase in relative risk from 4-fold to 30-fold caused by factor V Leiden heterozygosity, it is estimated that the 
combined risk would produce 15 deaths per million woman-years (compared to 4 deaths per million woman-
years caused by oral contraceptives alone).51,54 Based on the population frequency of the factor V Leiden 
allele, some have estimated that it would require screening as many as 2 million women to prevent one 
death.54 Furthermore, it would result in withholding oral contraceptives from 90,000 carriers identified in the 
screening process. These women would be obligated to turn to alternative, typically less effective, forms of 
contraception, with a resulting increase in pregnancy rate and its attendant complications (including, ironically, 
intrapartum and postpartum venous thromboembolism, as well as preeclampsia, placental abruption, and fetal 
growth retardation, which are also associated with factor V Leiden43). In addition, they would be exposed to all 
the potential psychosocial and insurance discrimination risks inherent in any genetic screening program.  
Recommendation 3  
Factor V Leiden testing is recommended in women with venous thromboembolism during pregnancy or oral 
contraceptive use. Routine screening for factor V Leiden in asymptomatic women contemplating or using oral 
contraceptives is not recommended, except for those with a personal or family history of thromboembolism or 
other medical risk factors. Those women with a family history of thromboembolism, APC resistance, or 
documented factor V Leiden mutation should be counseled about their risks and options and considered for 
testing, depending on the overall clinical situation. Women with a history of recurrent late-trimester fetal loss 
should also be considered for testing. Whether or not the woman smokes would not alter these 
recommendations. Screening of asymptomatic individuals with other recognized environmental risk factors such 
as surgery, trauma, paralysis, and malignancy is not necessary or recommended, since all such individuals 
should receive appropriate medical prophylaxis for thrombosis regardless of carrier status.  
4. Should patients found to be positive for factor V Leiden or APC resistance be tested for any of the other 
heritable thrombophilic risk factors?  
A growing constellation of heritable thrombophilic factors, some more accurately described as variants or 
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deficiency, antithrombin III deficiency, the prothrombin 20210A variant, hyperhomocysteinemia, and classical 
homocystinuria. The allele frequencies of some of these conditions are high enough that combined states of two 
or even three risk factors have been reported, with synergistic effects on relative risk.55-60 Thus, if a patient 
tests positive for factor V Leiden, it does not exclude the possibility that other genetic risk factors may be at work 
also. Some of these other defects are as easy to test for as factor V Leiden and can even be multiplexed in a 
single assay.61-63  
After factor V Leiden, the most common of the heritable thrombophilias are the prothrombin 20210A variant and 
hyperhomocysteinemia. The prothrombin variant is a single nucleotide change in the 3&cjs1227;-untranslated 
region of the gene that results in elevated circulating prothrombin levels through an unknown mechanism. It is 
present in 1-2% of the general Caucasian population and produces a phenotype similar to that of factor V 
Leiden. It is found in 6-8% of unselected patients with a first episode of venous thromboembolism.64 In addition, 
it has been associated with myocardial infarction in young women, cerebral vein thrombosis in oral 
contraceptive users, preeclampsia and other complications in pregnancy, and miscellaneous infarctions at other 
sites.43,64-67 Among patients with a first episode of venous thromboembolism, 10% of those identified as 
factor V Leiden heterozygotes will also have the prothrombin 20210A variant.  
A flurry of recent work has addressed the possible relationship of elevated plasma homocysteine levels with risk 
of both venous thromboembolic and cardiovascular disease. It has been known for a long time that these are 
common complications of homocystinuria, an inborn error of metabolism in which homocysteine levels are 
dramatically increased. Moreover, there is evidence that the risk of such events is heightened in homocystinuric 
patients who are also factor V Leiden carriers.55 More recently a more proportional gradation of risk has been 
associated with moderate physiologic elevations of plasma homocysteine in otherwise healthy adults, with 
relative risk beginning to increase as fasting plasma homocysteine concentration exceeds 10 µmol/liter.  
A product of methionine metabolism, homocysteine is maintained within a narrow range of concentrations 
through a complex series of reactions involving several enzymes and cofactors (the latter including vitamin B6, 
vitamin B12, and folic acid). Levels may rise as a result of subclinical deficiency of any of the enzymes involved, 
dietary deficiency of one of more of the cofactors, or a variety of other acquired medical conditions and lifestyle 
factors.68 Of the dietary factors, most recent attention has focused on folate intake, which is essential for 
metabolism of homocysteine via the remethylation pathway, catalyzed by N,5N10-methylenetetrahydrofolate 
reductase (MTHFR). Folate supplementation can lower homocysteine levels by enhancing this pathway, even in 
states of mild relative deficiency, such as that due to a common thermolabile variant (677C→T) of the MTHFR 
enzyme found in heterozygous form in 30-40% of the general population and homozygous form in 10-15%.69 
Because folic acid deficiency is also associated with risk of neural tube defects, dietary supplementation on a 
population-wide basis through fortification of grain products in the U.S. is now in progress; this action may yield 
secondary benefits on cardiovascular disease incidence as well. Still, the precise relation between 
hyperhomocysteinemia and cardiovascular disease or venous thromboembolism remains controversial.70-73 
Homozygosity for the 677C→T variant increases the risk for hyperhomocysteinemia, which in turn increases the 
risk of arterial thrombosis; but the variant by itself is not associated with arterial thrombosis in the absence of 
hyperhomocysteinemia, and is not associated with venous thrombosis in any case. As a simple point mutation 
(or point polymorphism), the 677C→T variant is easy to screen for using molecular methods; however, 
homozygosity for this mutation accounts for only about a third of cases of hyperhomocysteinemia. Therefore, 
many authorities feel plasma homocysteine measurement is more informative than molecular testing. 
Hyperhomocysteinemia interacts synergistically with coexisting factor V Leiden to increase the relative risk of 
venous thrombosis to 20-fold greater than in individuals without either risk factor.54  
Recommendation 4  
Patients testing positive for factor V Leiden or APC resistance should be considered for molecular genetic 
testing for the most common other thrombophilias with overlapping phenotype for which testing is easy and 
readily available. At present, only the prothrombin 20210A variant fits these criteria. It is present in 1-2% of the 
general population, its involvement in venous thromboembolism is well-established, and the DNA test is as 
simple as that for factor V Leiden (with which it can even be multiplexed). Protein S, protein C, and antithrombin 
III deficiencies are too genetically heterogeneous for routine molecular genetic testing, but testing by functional 
coagulation assays may be considered, especially if there is a strong family history of venous thrombosis. 
Hyperhomocysteinemia should be considered and tested (in most cases by measuring plasma homocysteine 
levels) as another potential risk factor in those found to be positive for factor V Leiden. Patients with classical 
homocystinuria are at extremely elevated risk of thromboembolism and should probably be tested for other 
available thrombophilic risk factors.  
5. Should testing for other heritable thrombophilic factors be performed simultaneously with factor V Leiden 
testing?  
Venous thrombosis is multifactorial, and the presence of more than one genetic risk factor is not uncommon. It 
could be argued that anyone presenting for factor V Leiden or APC resistance testing because of a thrombotic 
event already carries a risk factor for recurrent thrombosis even if found to be negative for factor V Leiden. 
Recurrent thrombosis carries a significant morbidity and mortality and is readily prevented by oral anticoagulant 
therapy, though not without significant risk of bleeding events. Therefore, it is important to identify patients at 
risk but to target anticoagulation therapy to those at highest risk. Such risk stratification is possible through 
panel testing of several common hereditary thrombophilic factors as well as acquired conditions such as lupus 
anticoagulant and/or anticardiolipin antibody. Standard functional coagulation assays performed on such 
patients are useful to detect defects in antithrombin III, protein C, and protein S; consideration should thus be 
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measurement of plasma homocysteine, and functional coagulation assays for antithrombin III, protein C, and 
protein S.  
Recommendation 5  
Physicians ordering factor V Leiden on a venous thrombosis patient for any of the indications recommended 
here should also consider the utility of functional, biochemical, and molecular screening for other heritable 
thrombophilic factors, especially prothrombin 20210A and plasma homocysteine levels.  
6. Are there any other factor V mutations in addition to factor V Leiden which should be tested?  
Factor V Leiden appears to account for 90-95% of cases of APC resistance. Two rare mutations in the factor V 
gene have been described and are of dubious clinical significance. Factor V-Cambridge (R306T) is not strongly 
associated with venous thrombosis in controlled epidemiologic studies.74 Factor V-Hong Kong (R306C) has 
been found in 1-2% of Chinese patients but does not appear to be associated with APC resistance.75  
The R2 allele (H1299R, or A4070G) of the factor V gene, associated with a haplotype known as HR2, is present 
in 10% of the general population, and early studies indicate that it increases the risk of venous thrombosis in 
individuals heterozygous for factor V Leiden an additional 3-fold beyond their already 7-fold increased risk.76 
Testing for R2 in factor V Leiden heterozygotes could potentially become useful if further larger studies support 
these early findings. R2 further reduces the sensitivity for APC in factor V Leiden heterozygotes.77,78 R2 alone, 
without coinheritance of factor V Leiden, neither reduces sensitivity for APC nor increases venous thrombosis 
risk.77,79 The R2 allele is not present in the same haplotype as factor V Leiden, so it is not possible for factor V 
Leiden homozygotes to have the R2 allele.  
Recommendation 6  
The factor V Leiden (R506Q) mutation is currently the only molecular analysis of the factor V gene indicated in 
the routine workup of thrombotic risk.  
7. What are the recommended methodologies and quality assurance standards for performing these tests?  
When performed properly using standard techniques, the factor V Leiden mutation test has extremely low false-
negative and false-positive rates, whether done by restriction endonuclease digestion of PCR amplicons (AMP-
FLPs), allele-specific PCR, allele-specific oligonucleotide probe hybridization, or other validated manual or 
automated methods. The traditional functional APC resistance test has very high sensitivity but suboptimal 
specificity for factor V Leiden.  
Recommendation 7  
The factor V Leiden mutation test should be performed using any of the accepted technical approaches as long 
as they have been properly validated by the laboratory, while adhering to current ACMG/CAP quality assurance 
guidelines for molecular genetic testing.  
8. What are the appropriate pre- and postanalytic procedures to be followed in factor V Leiden testing?  
Factor V Leiden testing is well established in mainstream medicine and is used by physicians from numerous 
specialties including hematology, internal medicine, primary care, and obstetrics. It is important that the genetic 
implications of factor V Leiden DNA test results be explained adequately by the health care professional 
conveying the test results to the patient.  
Recommendation 8  
Specific informed consent should not be required for factor V Leiden testing, but prior to testing, patients should 
be made aware that this is a genetic test, that test results have implications about risk in other family members, 
and that there may be attendant issues of confidentiality and possible insurance discrimination. The laboratory's 
report should state explicitly the relative risk implications for factor V Leiden heterozygotes and homozygotes, 
the risk that other relatives may have the mutation, and the recommendation, if indicated, for testing for other 
inherited hypercoagulabilities.  
It is important for individuals testing positive for factor V Leiden to understand the risk implications and genetic 
implications of their result. Patients should be counseled about these implications by their physician or genetic 
counselor.  
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This statement is designed primarily as an educational resource for medical geneticists and other health care 
providers to help them provide quality medical genetic services. Adherence to this statement does not 
necessarily ensure a successful medical outcome. This statement should not be considered inclusive of all 
proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining 
the same results. In determining the propriety of any specific procedure or test, the geneticist should apply his or 
her own professional judgment to the specific clinical circumstances presented by the individual patient or 
specimen. It may be prudent, however, to document in the patient's record the rationale for any significant 
deviation from this statement.
  © 2001-2006 American College of Medical Genetics. All rights reserved
Page 12 of 12 Consensus Statement on Factor V Leiden Mutation Testing
5/14/2007 http://www.acmg.net/resources/policies/pol-009.asp